Seelos Therapeutics EPS - Earnings per Share 2010-2022 | SEEL
Seelos Therapeutics eps - earnings per share from 2010 to 2022. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Seelos Therapeutics Annual EPS |
| 2021 |
$-0.73 |
| 2020 |
$-0.43 |
| 2019 |
$-2.52 |
| 2018 |
$-1.13 |
| 2017 |
$0.81 |
| 2016 |
$-34.54 |
| 2015 |
$-115.02 |
| 2014 |
$-165.17 |
| 2013 |
$-147.15 |
| 2012 |
$-348.35 |
| 2011 |
$-270.27 |
| 2010 |
$-747.75 |
| 2009 |
$-108.11 |
| Seelos Therapeutics Quarterly EPS |
| 2022-03-31 |
$-0.13 |
| 2021-12-31 |
$-0.24 |
| 2021-09-30 |
$-0.11 |
| 2021-06-30 |
$-0.10 |
| 2021-03-31 |
$-0.28 |
| 2020-12-31 |
$-0.12 |
| 2020-09-30 |
$-0.09 |
| 2020-06-30 |
$-0.08 |
| 2020-03-31 |
$-0.14 |
| 2019-12-31 |
$1.68 |
| 2019-09-30 |
$-0.13 |
| 2019-06-30 |
$-0.09 |
| 2019-03-31 |
$-3.98 |
| 2018-12-31 |
$-0.40 |
| 2018-09-30 |
$-0.36 |
| 2018-06-30 |
$-0.16 |
| 2018-03-31 |
$-0.21 |
| 2017-12-31 |
$-17.81 |
| 2017-09-30 |
$-8.71 |
| 2017-06-30 |
$-3.90 |
| 2017-03-31 |
$31.23 |
| 2016-12-31 |
$15.92 |
| 2016-09-30 |
$-5.71 |
| 2016-06-30 |
$-16.22 |
| 2016-03-31 |
$-28.53 |
| 2015-12-31 |
$-15.92 |
| 2015-09-30 |
$-30.03 |
| 2015-06-30 |
$-30.03 |
| 2015-03-31 |
$-39.04 |
| 2014-12-31 |
$-129.13 |
| 2014-09-30 |
$-24.02 |
| 2014-06-30 |
$15.02 |
| 2014-03-31 |
$-27.03 |
| 2013-12-31 |
$-12.01 |
| 2013-09-30 |
$-24.02 |
| 2013-06-30 |
$-36.04 |
| 2013-03-31 |
$-87.09 |
| 2012-12-31 |
$-198.20 |
| 2012-09-30 |
$-27.03 |
| 2012-06-30 |
$-57.06 |
| 2012-03-31 |
$-60.06 |
| 2011-12-31 |
$-66.07 |
| 2011-09-30 |
$-33.03 |
| 2011-06-30 |
$-117.12 |
| 2011-03-31 |
$-54.05 |
| 2010-12-31 |
$-222.22 |
| 2010-09-30 |
$-60.06 |
| 2010-06-30 |
$-141.14 |
| 2010-03-31 |
$-360.18 |
| 2009-12-31 |
$-102.10 |
| 2009-09-30 |
$-45.02 |
| 2009-06-30 |
$-90.05 |
| 2009-03-31 |
$45.02 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.106B |
$0.000B |
|
Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which are in clinical stage. Seelos Therapeutics Inc., formerly known as Apricus Biosciences Inc., is based in New York, United States.
|
